Announcements Trials
Browse Landscape

Phase

Phase 2 8Phase 3 3Phase 1/2 1Phase 1 1

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Myeloid 1

Conditions

Leukemia, Myeloid, Acute 2Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1

Interventions

Cisplatin 186Carboplatin 181Paclitaxel 177Docetaxel 145Cyclophosphamide 129Dexamethasone 117pembrolizumab 106Doxorubicin 103Bevacizumab 103Gemcitabine 102Rituximab 96Prednisone 87Fluorouracil 86Pemetrexed 81Radiotherapy 77Vincristine 71Etoposide 71Capecitabine 69Nivolumab 68Trastuzumab 67Leucovorin 64Cytarabine 57Methotrexate 52Oxaliplatin 49atezolizumab 48Lenalidomide 43Ipilimumab 40Filgrastim 40Bortezomib 39Sorafenib 38

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Has results × guadecitabine × Clear all
NCT02920008 2024-08-28

Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid Leukemia

Astex Pharmaceuticals, Inc.

Phase 3 Completed
302 enrolled 23 charts
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02348489 2024-08-27

SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission Induction

Astex Pharmaceuticals, Inc.

Phase 3 Completed
815 enrolled 19 charts
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02907359 2024-08-27

Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs

Astex Pharmaceuticals, Inc.

Phase 3 Completed
417 enrolled 24 charts
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡